Can posttraumatic stress disorder be prevented with glucocorticoids?

Area of Science:

• Critical care medicine
• Neuroscience
• Psychiatry

Background:

• Intensive care unit (ICU) survivors frequently experience traumatic memories and develop posttraumatic stress disorder (PTSD).
• Patients in ICUs often receive exogenous glucocorticoids for medical treatment.
• ICU stays offer a unique model to study glucocorticoid effects on traumatic memory and PTSD.

Purpose of the Study:

• To investigate the impact of glucocorticoid administration on traumatic memory recall and PTSD development in critically ill patients.
• To explore the potential of stress doses of hydrocortisone for preventing and treating PTSD in ICU survivors.

Main Methods:

• Analysis of traumatic memory categories (e.g., nightmares, pain) in long-term ICU survivors.
• Assessment of posttraumatic stress disorder (PTSD) symptom incidence and intensity.
• Evaluation of the effect of prolonged glucocorticoid administration (hydrocortisone stress doses) on PTSD symptoms post-recovery.

Main Results:

• A higher number of traumatic memory categories correlated with increased PTSD symptom incidence and intensity.
• Prolonged hydrocortisone administration significantly reduced PTSD symptoms after recovery.
• Glucocorticoid treatment did not affect the number of traumatic memory categories recalled.

Conclusions:

• Stress doses of hydrocortisone may reduce PTSD symptoms in ICU patients.
• Cortisol's protective effect might stem from temporary impairment of traumatic memory retrieval.
• Hydrocortisone could be a valuable tool for PTSD prophylaxis and treatment in critical care settings.